Barfield Elaine, Sockolow Robbyn, Hoffenberg Edward, Saeed Shehzad, Kim Sandra, Siebold Leah, Picoraro Joseph, Moses Jonathan, Dykes Dana, Grossman Andrew, Wahbeh Ghassan, Park K T
Department of Pediatrics, Division of Gastroenterology and Nutrition, Weill Cornell Medicine, New York, NY.
Center for Pediatric Inflammatory Bowel Disease, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO.
J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):680-686. doi: 10.1097/MPG.0000000000001890.
The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease. Patients in North America are increasingly denied coverage by payers based on "place of service" codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with inflammatory bowel disease receiving non-hospital-based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.
北美儿科胃肠病学、肝病学和营养学会发布的这份临床报告的主要目的是,就儿科炎症性肠病生物疗法的家庭和门诊输液,为儿科胃肠病学家和临床医生、医疗系统及保险支付方提供正式指导。在北美,基于治疗临床医生主要提供护理的医院输液单位的“服务地点”代码,患者越来越多地被支付方拒绝承保。一个具有主题专业知识的特别工作组提出了8项最佳实践建议,以确保接受非医院生物输液的儿科炎症性肠病患者的护理质量。本报告中讨论的实际考虑因素包括患者安全、具备儿科培训经验的护士可用性、护理协调、以患者为中心、共同责任、行政支持、临床治理以及护理成本。